SuperworthArcus Biosciences EPS RCUS
Diluted earnings per share by quarter and over the last twelve months, from 2017.
- Last 12 months, to Jun 30, 2026
- −$3.91
- Latest quarter, Q2 FY26
- −$0.72
- Fiscal year 2025
- −$3.31
Arcus Biosciences' earnings per share was −$3.91 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.72.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$3.31 | n/a |
| FY2024 | −$3.10 | n/a |
| FY2023 | −$4.15 | n/a |
| FY2022 | −$3.72 | −945% |
| FY2021 | $0.44 | n/a |
| FY2020 | −$2.35 | n/a |
| FY2019 | −$1.94 | n/a |
| FY2018 | −$2.22 | n/a |
| FY2017 | −$28.43 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.72 | n/a | −$3.91 | |
| Q1 FY26 | −$1.02 | n/a | −$3.19 | |
| Q4 FY25 | −$0.90 | n/a | −$3.31 | |
| Q3 FY25 | −$1.27 | n/a | −$3.44 | |
| Q2 FY25 | $0.00 | n/a | −$3.17 | |
| Q1 FY25 | −$1.14 | n/a | −$4.19 | |
| Q4 FY24 | −$1.03 | n/a | −$3.10 | |
| Q3 FY24 | −$1.00 | n/a | −$3.15 | |
| Q2 FY24 | −$1.02 | n/a | −$3.09 | |
| Q1 FY24 | −$0.05 | n/a | −$3.11 | |
| Q4 FY23 | −$1.08 | n/a | −$4.15 | |
| Q3 FY23 | −$0.94 | n/a | −$4.00 |
Against its peers
Companies in Drug Manufacturers - General nearest Arcus Biosciences' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| RCUSArcus Biosciences | −$3.91 | |
| PBHPrestige Consumer Healthcare | $3.57 | −16% a year |
| HRMYHarmony Biosciences | $3.09 | −0% a year |
| NRIXNurix Therapeutics | $2.31 | |
| ANIPANI Pharmaceuticals | $4.70 | |
| PAHCPhibro Animal Health | $2.44 | +107% a year |
| OGNOrganon | $0.77 | −71% a year |
| LQDALiquidia | $1.39 | |
| ANABAnaptysbio | $4.57 | |
| PCRXPacira BioSciences | $0.35 | |
| ARQTArcutis Biotherapeutics | $0.22 | |
| Peer median | $2.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Arcus Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.